Palbociclib improves cardiac dysfunction in diabetic cardiomyopathy by regulating Rb phosphorylation

Area of Science:

• Cardiology
• Endocrinology
• Pharmacology

Background:

• Diabetic cardiomyopathy (DCM) involves cardiac tissue necrosis, fibrosis, and cardiomyocyte hypertrophy.
• Cyclin-dependent kinases 4 and 6 (CDK4/6) are implicated in cardiac remodeling.
• Diabetic cardiomyopathy poses a significant clinical challenge.

Purpose of the Study:

• To investigate the therapeutic potential of Palbociclib, a CDK4/6 inhibitor, in a mouse model of diabetic cardiomyopathy.
• To elucidate the mechanisms by which Palbociclib affects DCM-related pathological changes.

Main Methods:

• A streptozotocin (STZ)-induced diabetic cardiomyopathy mouse model was utilized.
• Mice were treated with Palbociclib following STZ administration.
• Cardiac function, oxidative stress, inflammation, and cardiomyocyte death were assessed.
• Expression of CDK4, CDK6, and Rb phosphorylation was analyzed.

Main Results:

• CDK4 and CDK6 expression were significantly elevated in the cardiac tissue of STZ-induced DCM mice.
• Palbociclib treatment attenuated oxidative stress and inflammation.
• Palbociclib reduced cardiomyocyte death and preserved cardiac function.
• Rb phosphorylation, induced by STZ, was inhibited by Palbociclib.

Conclusions:

• Palbociclib demonstrates protective effects against STZ-induced diabetic cardiomyopathy in mice.
• The therapeutic benefits of Palbociclib involve the mitigation of oxidative stress, inflammation, and cardiomyocyte death.
• Palbociclib represents a potential therapeutic target for managing diabetic cardiomyopathy.